Ovarian cancer tests don't cut risk of death in study

05/18/2011 | HealthDay News

Data on about 80,000 women found no statistically significant difference in diagnoses of ovarian cancer or death rates between screening with a blood test for a marker called CA-125 and transvaginal ultrasound. Researchers also found that the tests resulted in false positive diagnoses among nearly 3,300 women, including 1,100 who underwent surgical biopsies and 163 who developed serious complications. The study will be presented at the annual meeting of the American Society of Clinical Oncology.

View Full Article in:

HealthDay News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY